Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Purepac

Executive Summary

Has marketed a generic version of Warner-Lambert's Eryc since August. Purepac's parent Faulding is the innovator of the delayed- release erythromycin product, which it exclusively licensed to Warner-Lambert until August. Purepac said it has experienced a significant increase in demand for the erythromycin product since Warner-Lambert and Barr Labs suspended distribution of their products due to manufacturing difficulties ("The Pink Sheet" May 10, T&G-10).
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS022629

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel